Pharmacological approaches to the prevention of restenosis after coronary angioplasty

Drugs and Aging

Volumn 13, Issue 4, 1998, Pages 291-301

  Hamon, Martial ^a,c   Lécluse, Emmanuel ^a   Monassier, Jean Pierre ^b   Grollier, Gilles ^a   Potier, Jean Claude ^a  

^a UNIVERSITÉ DE CAEN   (France)

^b CENTRE HOSPITALIER DE MULHOUSE   (France)

^c CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; GROWTH FACTOR; PROSTACYCLIN DERIVATIVE; SULFINPYRAZONE; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; TICLOPIDINE; VASODILATOR AGENT;

CORONARY ARTERY DISEASE; HUMAN; HYPERPLASIA; INTIMA; MAJOR CLINICAL STUDY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RESTENOSIS; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTICOAGULANTS; GRAFT OCCLUSION, VASCULAR; HEMATOLOGIC AGENTS; HUMANS; PLATELET AGGREGATION INHIBITORS;

EID: 7844250137     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199813040-00005     Document Type: Review

References (100)

1. Bauters C, Lablanche J-M, McFadden EP, et al. Clinical characteristics and angiographic follow-up of patients undergoing early and late repeat dilation for a first restenosis. J Am Coll Cardiol 1992; 20: 845-8
2. Hamon M, Bauters C, McFadden EP, et al. Restenosis after coronary angioplasty. Eur Heart J 1995; 116 Suppl. 1: 33-48
3. Herrrnan J-PR, Hermans WRM, Vos J, et al. Pharmacological approaches to the prevention of restenosis following angioplasty: the search for the holy grail? (part I). Drugs 1993; 46: 18-52
4. Franklin SM, Faxon DP. Pharmacologic prevention of restenosis following angioplasty; review of the randomized clinical trials. Coron Artery Dis 1993; 4: 232-42
5. Schwartz SM, deBlois D, O'Brien ERM. The intima - soil for atherosclerosis and restenosis. Circ Res 1995; 77: 445-65
6. Bauters C, De Groote P, Adamantidis M, et al. Proto-oncogene expression in rabbit aorta after wall injury: first marker of the cellular process leading to restenosis after angioplasty? Eur Heart J 1992; 13: 556-9
7. Hamon M, Bauters C, Wernert N, et al. Heparin does not inhibit oncogene induction in rabbit aorta following balloon denudation. Cardiovasc Res 1993; 27: 1209-13
8. Miano JM, Viasic N, Tota RR, et al. Localisation of fos and jun proteins in rat aortic smooth muscle cells after vascular injury. Am J Pathol 1993; 142: 715-24
9. Pardee AB. G1 events and regulation of cell proliferation. Science 1989; 246: 603-8
10. Reed JC, Alpers JD, Nowell PC, et al. Sequential expression of protooncogenes during lectin-stimulated mitogenesis of normal human lymphocytes. Proc Natl Acad Sci U S A 1986; 83: 3982-6
11. Thyberg J, Hedin U, Sjolund M, et al. Regulation of differentiated properties and proliferation of arterial smooth muscle cells. Arteriosclerosis 1990; 10: 966-90
12. Schwartz SM, Campbell CR, Campbell JH. Replication of smooth muscle cells in vascular disease. Circ Res 1986; 58: 427-44
13. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury: I. smooth muscle growth in the absence of endothelium. Lab Invest 1983; 49: 327-33
14. Rubbia L, Gabbiani G. The cytoskeleton of arterial smooth muscle cells during development, atheromatosis and tissue culture. J Cardiovasc Pharmacol 1989; 14 Suppl. 6: S9-S11
15. Boyd CD, Kniep AC, Pierce RA, et al. Increased elastin mRNA levels associated with surgically induced intimal injury. Connect Tissue Res 1988; 18: 65-78
16. Bauters C, Marotte F, Hamon M, et al. Accumulation of fetal fibronectin mRNAs after balloon denudation of rabbit arteries. Circulation 1995; 92: 904-11
17. Schwartz RS, Holmes DR, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992; 20: 1284-93
18. Clowes AW, Clowes MM, Kocher O, et al. Arterial smooth muscle cells in vivo: relationship between actin isoform expression and mitogenesis and their modulation by heparin. J Cell Biol 1988; 107: 1939-45
19. Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316: 1371-5
20. Post MJ, Borst C, Kuntz RE. The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty: a study in the normal rabbit and in the hypercholesterolemic Yucatan micropig. Circulation 1994; 89: 2816-21
21. Kakuta T, Currier JW, Haudenschild CC, et al. Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model. Circulation 1994; 89: 2809-15
22. Lafont A, Guzman LA, Whitlow PL, et al. Restenosis after experimental angioplasty: intimal, medial, and adventitial changes associated with constrictive remodeling. Circ Res 1995; 76: 996-1002
23. Austin GE, Norman NB, Hollman J, et al. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985; 6: 369-75
24. Johnson DE, Hinohara T, Selmon MR, et al. Primary peripheral arterial stenoses and restenoses excised by transluminal atherectomy: a histopathologic study. J Am Coll Cardiol 1990; 15: 419-25
25. Ueda M, Becker AK, Tsukada T, et al. Fibrocellular tissue response after percutaneous transluminal coronary angioplasty: an histochemical analysis of the cellular composition. Circulation 1991; 83: 1327-32
26. Mintz GS, Popma JJ, Pichard AD, et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 1996; 94: 35-43
27. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis: a serial intravascular ultrasound study. Circulation 1996; 94: 1247-54
28. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489-95
29. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331: 496-501
30. Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988; 318: 1714-9
31. White CW, Knuddson M, Schmidt D, et al. Neither ticlopidine nor aspirin and dipyridamole in the prevents of restenosis post-PTCA: results from a randomized placebo-controlled multi-center trial [abstract]. Circulation 1987; 76 Suppl. 4: 213
32. Kadel C, Vailbracht C, Weidmann B, et al. Aspirin and restenosis after successful PTCA: comparison of 1400mg vs 350mg daily in a double blind study [abstract]. Eur Heart J 1990; 11 Suppl.: 368
33. Bertrand ME, Alain H, Lablanche JM. Results of a randomized trial of ticlopidine versus placebo for the prevention of acute closure and restenosis after coronary angioplasty: the TACT study [abstract]. Circulation 1990; 82 Suppl. 2: 190
34. Kitazume H, Kubo I, Iwama T, et al. Combined use of aspirin ticlopidine and nicorandil prevented restenosis after coronary angioplasty [abstract]. Circulation 1988; 78 Suppl. 2: 633
35. Pepine CJ, Hirshfeld JW, MacDonald RG, et al. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. Circulation 1990; 81: 1753-61
36. O'Keefe JH, McCallister BD, Bateman LV, et al. Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. J Am Coll Cardiol 1992; 19: 1597-600
37. Emanuelsson H, Beatt KJ, Bagger JP, et al. Long term effects of angiopeptin treatment in coronary angioplasty: reduction of clinical events but not angiographic restenosis. Circulation 1995; 91: 1689-96
38. von Essen R, Ostermaier R, Grube E, et al. Effects of octreotide treatment on restenosis after coronary angioplasty. Results of the VERAS study. Circulation 1997; 96: 1482-7
39. Maresta A, Balducelli M, Cantini L, et al. Trapidil, a platelet-derived growth factor antagonist reduces restenosis after percutaneous transluminal coronary angioplasty: results of the randomized double blind STARC study. Circulation 1994; 90: 2710-5
40. The MERCATOR study group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? The results of the MERCATOR study: a multi-center randomized, double-blind, placebo-controlled trial. Circulation 1992; 86: 100-10
41. Desmet W, Vrolix M, De Ssheerder L, et al. Angiotensin-converting-enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty. Circulation 1994; 89: 385-92
42. Faxon DP. on behalf of the MARCATOR investigators. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of cilazapril. J Am Coll Cardiol 1995; 25: 362-9
43. Serruys PW, Herrman JP, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. For the HELVETICA Investigators. N Engl J Med 1995; 333: 757-63
44. Faxon D, Spiro T, Minor S, et al. Low molecular weight heparin in the prevention of restenosis after angioplasty: results of enoxaparin restenosis (ERA) trial. Circulation 1994; 90: 908-14
45. Lablanche JM, McFadden EP, Meneveau N, et al. Effect of Nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty. The FACT study. Circulation 1997; 96: 3396-402
46. Weintraub WS, Bocuzzi SJ, Klein JL, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 1994; 331: 1331-7
47. Bertrand ME, McFadden EP, Fruchart J-C, et al. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. J Am Coll Cardiol 1997; 30: 863-9
48. Tardif J-C, Côté G, Lespérance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997; 337: 365-72
49. Yokoi H, Daida H, Kuwahara Y, et al. Effectiveness of an anti-oxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the prohucol angioplasty restenosis trial. J Am Coll Cardiol 1997; 30: 855-62
50. Grigg LE, Kay TWH, Valentine PA, et al. Determinants of restenosis and lack of effect of dietary supplementation with eicosapentaenoic acid on the incidence of coronary artery restenosis after angioplasty. J Am Coll Cardiol 1989; 13: 665-72
51. Bairati L, Roy L, Meyer F. Double-blind randomized controlled trial of fish oil supplements in prevention of the recurrence of stenosis after coronary angioplasty. Circulation 1992; 85: 950-6
52. Franzen D, Schannwell M, Oette K, et al. A prospective, randomized, and double blind trial on the effect of fish oil on the incidence of restenosis following PTCA. Cathet Cardiovasc Diagn 1993; 28: 301-111
53. Leaf A, Jorgensen MB, Jacobs AK, et al. Do fish oils prevent restenosis after coronary angioplasty? Circulation 1994; 90: 2248-57
54. Feldman RL, Bengston JR, Pryor DB, et al. The GRASP study Group. Use of thromboxane A2 receptor blocker to reduce adverse clinical events after coronary angioplasty [abstract]. J Am Coll Cardiol 1942; 19: 254
55. Savage MP, Goldberg S, Bove AA, et al. Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty; multi-hospital eastern atlantic restenosis trial (M-Heart). Circulation 1995; 92: 3194-200
56. Knudtson ML, Flintoft VF, Roth DL, et al. Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1990; 15: 691-7
57. Gershlick AH, Timmis AD, Tothman MT, et al. Post-angioplasty prostacyclin infusion does not reduce the incidence of restenosis [abstract]. Circulation 1990; 82 Suppl. 2: 497
58. Raizner AE, Hollman J, Demke D, et al. Beneficial effects of ciprostene in PTCA: a multicenter, randomized, controlled trial [abstract]. Circulation 1988; 78 Suppl. 2: 290
59. O'Keefe JH, Giorgi LV, Hartzler GO, et al. Effects of diltiazem on complications and restenosis after coronary angioplasty. Am J Cardiol 1991; 67: 373-6
60. Whitworth HB, Roubin OS, Hoilman J, et al. Effect of nifedipine on recurrent stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1986; 8: 1271-6
61. Unverdorben M, Kundel B, Leucht M, et al. Reduction of restenosis after PTCA by diltiazem [abstract]. Circulation 1992; 86 Suppl. 1: 53
62. Hoberg E, Dietz R, Frees U, et al. Verapamil treatment after coronary angioplasty in patients at high risk of recurrent stenosis. Br Heart J 1994; 71: 254-60
63. Serruys PW, Klein W, Tijssen JPG, et al. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty: a multi-center randomized double-blind placebo-controlled trial. Circulation 1993; 88: 1588-601
64. Lablanche JM, Grollier G, Lusson J, et al. Effect of the direct nitric oxide donors linsidomine and molsidomine on angiographic restenosis after coronary balloon angioplasty. The ACCORD study: angioplastic coronaire corvasal diltiazem. Circulation 1997; 95: 83-9
65. Bauters C, Hamon M, Van Belle E, et al. Resténose après angioplastie coronaire: apport des modèles expérimentaux. Arch Mal Cœur Vaiss 1993; 86: 47-56
66. Fingerle J, Johnson R, Clowes AW, et al. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. Proc Natl Acad Sci USA 1989; 86: 8412-6
67. Goldberb ID, Stemerman MB. Vascular permeation of platelet factor 4 after endothelial injury. Science 1980; 209: 611-2
68. Friedman RJ, Stemerman MB, Wenz B. et al. The effect of thrombocytopenia on experimental arteriosclerotic lesion formation in rabbits. J Clin Invest 1977; 60: 1191-201
69. Faxon DP, Sanborn TA, Haudenschild CC, et al. Effect of anti-platelet therapy on restenosis after experimental angioplasty. Am J Cardiol 1984; 53: 72C-6C
70. Serruys PW, Rutsch W, Heyndrickx GR, et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2 receptor blockade: a randomized, double blind, placebo controlled trial (CARPORT study). Circulation 1991; 84: 1568-81
71. Topol EJ, Califf RM, Weisman HF, et al. Randomized trial of coronary intervention against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 881-6
72. Majesky MW, Schwartz SM, Clowes MM, et al. Heparin regulates smooth muscle S phase entry in the injured rat carotid artery. Circ Res 1987; 61: 296-300
73. Clowes AW, Clowes MM. Kinetics of cellular proliferation after arterial injury: II. inhibition of smooth muscle growth by heparin. Lab Invest 1985; 52: 611-6
74. Ellis SG, Roubin GS, Wilentz J, et al. Effect of 18-24 hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989; 117: 777-82
75. Sarembock IJ, Gertz SD, Gimple LW, et al. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1991; 84: 232-43
76. Daemen MJAP, Lombardi DM, Bosman FT, et al. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991; 68: 450-6
77. Powel JS, Clozel JP, Muller RKM, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989; 245: 186-8
78. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-6
79. Costerousse O, Allegrini J, Lopez M, et al. Angiotensin-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T lymphocytes. Biochem J 1993; 290: 33-40
80. Hamon M, Bauters C, Amant C, et al. Relation between the deletion polymorphism of the angiotensin-converting enzyme gene and late luminal narrowing after coronary angioplasty. Circulation 1995; 92: 296-9
81. Hamon M, Amant C, Bauters C, et al. ACE polymorphism, a genetic predictor of occlusion after coronary angioplasty. Am J Cardiol 1996; 78: 679-81
82. Amant C, Bauters C, Bodart J-C, et al. D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. Circulation 1997; 96: 56-60
83. Leaf A, Weber PC. Cardiovascular effects of n-3 fatty acids. N Engl J Med 1990; 318: 549-57
84. Dehmer GJ, Popma JJ, Van Den Berg EK, et al. Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids. N Engl J Med 1988; 319: 733-40
85. Reis GJ, Boucher TM, Sipperly ME, et al. Randomized trial of fish oil for prevention of restenosis after coronary angioplasty. Lancet 1989; II: 177-81
86. Gellman J, Ezekowitz MD, Sarembock IJ, et al. Effect of lovastatin on intimal hyperplasia after balloon angioplasty: a study in an atherosclerotic hypercholesterolemic rabbit. J Am Coll Cardiol 1991; 17: 251-9
87. Liu MW, Roubin GS, Robinson KA, et al. Trapidil in preventing restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation 1990; 81: 1089-93
88. Lundergan C, Foegh ML, Vargas R. Inhibition of myointimal proliferation of the rat carotid artery by the peptides angiopeptin and BIM 23034. Atherosclerosis 1989; 80: 49-55
89. Lundergan CF, Foegh ML, Ramwell PW. Peptide inhibition of myointimal proliferation by angiopeptin, a somatostatin analogue. J Am Coll Cardiol 1991: 17 Suppl.: 132B-6B
90. Bauters C, Van Belle E, Wernert N, et al. Angiopeptin inhibits oncogene induction in rabbit aorta after balloon denudation. Circulation 1994; 89: 2327-31
91. Kent KM, Williams DO, Cassagneau B, et al. Double blind, controlled trial of the effect of angiopeptin on coronary restenosis following balloon angioplasty [abstract]. Circulation 1993; 88 Suppl. 1: 506
92. Garg UC, Hassid A. Nitric oxide-generating vasodilatators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774-7
93. Cooke JP, Singer AH, Tsao P, et al. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992; 90: 1168-72
94. Hamon M, Vallet B, Bauters C, et al. Long term oral administration of L-arginine reduces intimal thickening and enhances neoendothelium-dependent acetylcholine-induced relaxation after arterial injury. Circulation 1994; 90: 1357-62
95. Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992; 19: 267-74
96. Santoian EC, Schneider JE, Gravanis MB, et al. Angiopeptin inhibits intimal hyperplasia after angioplasty in porcine coronary arteries. Circulation 1993; 88: 11-4
97. Wolinsky H, Thung SN. Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. J Am Coll Cardiol 1990; 15: 475-81
98. Wilensky RL, March KL, Hathaway DR. Direct intraarterial wall injection of microparticles via a catheter: a potential drug delivery strategy following angioplasty. Am Heart J 1991; 122: 1136-40
99. Serruys PW, Emanuelsson H, van der Giessen W, et al. Heparin-coated Palmaz-Schatz stents in human coronary arteries: early outcome of the Benestent-II pilot study. Circulation 1996; 93: 412-22
100. Condado JA, Waksman R, Gurdiel O, et al. Long-term angiographic and clinical outcome after percutaneous transluminal coronary angioplasty and intracoronary radiation therapy in humans. Circulation 1997; 96: 727-32